MYD88 and B-cell chronic lymphocytic leukemia: In CLL cells, ND2158 decreases cell viability independently of MYD88 mutational status and inhibits tumor proliferation promoted by the TLR agonists, resulting in blockade of NF-κB and STAT3 signaling.